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Abstract
Objectives To assess whether MRI can exclude axillary
lymph node metastasis, potentially replacing sentinel lymph
node biopsy (SLNB), and consequently eliminating the risk of
SLNB-associated morbidity.
Methods PubMed, Cochrane, Medline and Embase databases
were searched for relevant publications up to July 2014. Stud-
ies were selected based on predefined inclusion and exclusion
criteria and independently assessed by two reviewers using a
standardised extraction form.
Results Sixteen eligible studies were selected from 1,372 pub-
lications identified by the search. A dedicated axillary proto-
col [sensitivity 84.7 %, negative predictive value (NPV)
95.0 %] was superior to a standard protocol covering both
the breast and axilla simultaneously (sensitivity 82.0 %,
NPV 82.6 %). Dynamic, contrast-enhanced MRI had a lower
median sensitivity (60.0 %) and NPV (80.0 %) compared to
non-enhanced T1w/T2w sequences (88.4, 94.7 %), diffusion-
weighted imaging (84.2, 90.6 %) and ultrasmall
superparamagnetic iron oxide (USPIO)- enhanced T2*w se-
quences (83.0, 95.9 %). The most promising results seem to
be achievable when using non-enhanced T1w/T2w and
USPIO-enhanced T2*w sequences in combination with a ded-
icated axillary protocol (sensitivity 84.7 % and NPV 95.0 %).
Conclusions The diagnostic performance of some MRI pro-
tocols for excluding axillary lymph node metastases ap-
proaches the NPV needed to replace SLNB. However, current
observations are based on studies with heterogeneous study
designs and limited populations.
Main Messages
• Some axillaryMRI protocols approach the NPVof an SLNB
procedure.
• Dedicated axillary MRI is more accurate than protocols
also covering the breast.
• T1w/T2w protocols combined with USPIO-enhanced se-
quences are the most promising sequences.
Keywords Breast cancer .MRI . Axilla . Lymph nodes .
Neoplasmmetastases
Introduction
Some 15 years ago, sentinel lymph node biopsy (SLNB) re-
placed axillary lymph node dissection (ALND) for nodal stag-
ing in clinically node-negative breast cancer patients. Al-
though less invasive compared to ALND, the SLNB is still
associated with non-neglible morbidity. For example, lymph
oedema is reported in 5–8 % of patients after an SLNB [1, 2].
Other common complications are pain, paresthesia, decreased
arm strength and shoulder stiffness [3]. Sixty percent of newly
diagnosed breast cancer patients are pathologically node neg-
ative and consequently do not benefit from SLNB. Nonethe-
less, these patients are at risk of its complications.
As a result, there is a continuous search for novel, non-
invasive nodal staging techniques that can accurately identify
lymph node-negative breast cancer patients. Hypothetically, a
non-invasive technique with high sensitivity and negative
V. J. L. Kuijs :R. J. Schipper : R. G. H. Beets-Tan :
M. B. I. Lobbes (*)
Department of Radiology and Nuclear Medicine, Maastricht
University Medical Center+, PO Box 5800, 6202
AZ Maastricht, The Netherlands
e-mail: marc.lobbes@mumc.nl
V. J. L. Kuijs :M. Moossdorff :R. J. Schipper : E. M. Heuts :
K. B. M. I. Keymeulen :M. L. Smidt
Department of Surgery, Maastricht University Medical Center+, PO
Box 5800, 6202 AZ Maastricht, The Netherlands
M. Moossdorff : R. J. Schipper :R. G. H. Beets-Tan :M. L. Smidt :
M. B. I. Lobbes
GROW- School for Oncology and Developmental Biology, PO Box
616, 6200 MD Maastricht, The Netherlands
Insights Imaging (2015) 6:203–215
DOI 10.1007/s13244-015-0404-2
predictive value (NPV) could replace SLNB, eliminating its
morbidity risk. Very small metastases will be hard to detect
with any imaging technique, but recent studies have shown
that these small metastases, such as isolated tumour cells (i.e.,
N0i+, <0.2 mm) and micrometastases (i.e., N1mi,
0.2–2.0 mm), do not influence overall survival. Consequently,
sensitivity for detecting very small metastases is less impor-
tant [4], creating a window of opportunity for (non-invasive)
imaging techniques that might be able to perform axillary
staging of breast cancer patients.
In recent years, many non-invasive imaging modalities,
such as ultrasound or PET-CT, have been suggested for this
purpose. We opted to systematically review the current evi-
dence of axillary staging using MRI, since it appears to have
several advantages over other imaging modalities, such as the
lack of ionising radiation (compared to PET/CT) or less intra-
and interobserver variation (common in ultrasound
examinations).
The aim of this systematic review is to determine whether
the diagnostic performance of MRI is sufficient to confidently
exclude axillary lymph node metastasis in breast cancer pa-
tients, preventing node-negative patients from undergoing un-
necessary invasive staging procedures such as SLNB.
Materials and methods
Search strategy
For this systematic review, the guidelines of Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) were followed [5]. A literature search was per-
formed in the Cochrane Library, Embase and PubMed data-
bases up to July 2014. Search terms used were breast or mam-
ma combined with the terms neoplasms, malignancy, cancer,
carcinoma and adenocarcinoma. Terms for intervention were
magnetic resonance imaging, MRI, MR mammography, MR,
and magnetic resonance. Terms for the reference test were
axilla, axillary, lymph, node, nodal, stage, status, staging,
lymph nodes, lymphatic metastases, sentinel lymph node bi-
opsy, lymph node excision, axillary lymph node dissection,
ALND, SLNB, sentinel lymph node, SN and sentinel node.
Outcome terms were sensitivity, specificity, negative predic-
tive value, NPV, positive predictive value, PPVand accuracy.
A manual search of the reference lists of retrieved articles was
performed for any additional publications.
In- and exclusion criteria
To avoid selection bias, in- and exclusion criteria were
established prior to the literature search. Inclusion criteria
were (1) diagnostic research, (2) newly diagnosed, histologi-
cally proven breast cancer patients, (3) at least 15 patients in
the final analysis, (4) patients underwent standard breast MRI
or dedicated axillary MRI prior to surgery, (5) minimum mag-
netic field strength of 1.5 T and (6) pathological examination
was based on SLNB or ALND.
Additional exclusion criteria were (1) not addressing nodal
staging; (2) studies with patients undergoing any type of neo-
adjuvant chemo-, immune- or endocrine therapy; (3) patients
with a history of axillary surgery or treatment; (4) patients
with recurrent axillary disease; (5) studies without >3 of the
following diagnostic performance parameters: sensitivity,
specificity, PPV, NPV or accuracy; (6) editorials, conference
publications, surveys, case reports, reviews, meta-analysis,
ex vivo studies and animal studies.
Study selection
Two independent reviewers searched for eligible articles and
excluded duplicates. First, irrelevant articles based on the ab-
stract and title were excluded by one reviewer and verified by
the second one. Second, predefined in- and exclusion criteria
were applied. Third, the full text of the remaining articles was
obtained and considered by both reviewers. The study selec-
tion process did not apply any time or language restrictions. In
the last phase, only two articles were additionally excluded
(Spanish and Chinese).
Data extraction and quality assessment
Data from the included studies were extracted by both re-
viewers in consensus, using a standardised extraction form.
The following data were collected: first author, year of publi-
cation, study design (retrospective or prospective), population
size, mean patient age and range, magnetic field strength,
breast MRI (i.e., covering the breast and axilla together) or
‘dedicated’ axillary MRI (i.e., specifically designed for imag-
ing of the axilla), radiofrequency coil used, imaging sequences
acquired, contrast agent used, voxel size, imaging analysis,
timing of surgery, breast cancer and nodal stage at inclusion,
tumour histology, pathological assessment, prevalence of nod-
al metastases and diagnostic performance parameters such as
sensitivity, specificity, NPV, PPVand accuracy.
Both reviewers assessed the quality of the articles using the
Quality Assessment of Diagnostic Accuracy Studies 2
(QUADAS-2) checklist [6]. P-values≤0.05 were considered
statistically significant. As this is a systematic review, no ap-
proval from an institutional review board was required.
Results
A total of 1,372 potentially eligible studies were identified in
the primary search. After a first selection 1,220 articles were
excluded. Of the remaining 152 studies, duplicates between
204 Insights Imaging (2015) 6:203–215
various searches were removed, leaving 98 studies. During a
second selection, abstracts of the remaining 98 studies were
read and in- and exclusion criteria were applied, leaving 15
studies to be reviewed. One additional study was found in the
references of an included article, and after applying the in- and
exclusion criteria, it was included in this review. Therefore, a
total of 16 articles were selected for this systematic review
[7–22]. The search and selection processes are summarised
in Fig. 1.
Publication characteristics
Twelve of the 16 included studies (75 %) had a prospective
study design [9–11, 13–19, 21, 22]. The included studies
contained a total of 1,591 patients (mean 99 per study, range
18–505). Patient age ranged from 43 to 62 years. Only three
articles reported the exact time frame between MRI and sur-
gery (within a mean of 6.7 days, range 1–14 days) [18, 19,
22].
Technical MRI details
In all but one study a 1.5-T MRI was used; in the remaining
study both a 1.5- and a 3.0-T MRI system was used [12].
Unenhanced T1w or T2*w imaging was used in three studies
[10, 14, 16], seven studies used dynamic contrast-enhanced
T1w imaging sequences [7, 9, 11, 12, 17, 20, 21], six studies
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Fig. 1 Flowchart of study
selection process according to the
Preferred Reporting Items for
Systematic Reviews and Meta-
Analyses (PRISMA)
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and two studies used ultrasmall superparamagnetic iron oxide
(USPIO) enhanced T2*w imaging sequences [18, 22]. Only 5
studies used a protocol dedicated to the axilla [11, 14, 16, 18,
22]; the other 11 used a coil covering both the breast and axilla
[7–10, 12, 13, 15, 17, 19–21]. Intravenous contrast adminis-
tration was used in 12 studies; agents used were gadodiamide
[11, 21], gadobenate dimeglumine [7–9, 20], gadoterate
meglumine [19], gadobutrol [12] and USPIO ferumoxtran-
10 [18, 22]. In two studies, the type of contrast was not
reported[15, 17]. Criteria for distinguishing positive from neg-
ative nodes varied to a large extent; size, short/long axis ratio,
lymph nodes >4 mm, short axis diameter >5 or >10 mm,
shape, irregular margins, lobulated margins, presence of fatty
hilum, cortical thickening, cortical thickness >3 mm, asym-
metric cortex, unclear margins, perinodular oedema, matting,
anatomical location of the lymph node, signal intensity time
curves, heterogeneous uptake of USPIO, lack of USPIO up-
take, T2* values, high signal intensity on DWI, early stage
enhancement, apparent diffusion coefficient (ADC) values,
visual inspection of DWI and ADC and detectability on DWI.
Reference test
Eight studies reported the method of their pathologic analysis
of the lymph nodes [7, 9, 12, 14, 16, 18, 19, 22], which
consisted of sectioning of the long or short axis or both, sec-
tioning of parallel slices of 2–4 mm thickness, H&E staining,
conventional microscopic examination, the position of the
lymph nodes, examination of the residual fatty tissue to detect
any small lymph nodes and immunohistochemical assay. Five
studies did not further specify the used pathologic examina-
tion (“histopathological examination”, “pathologically con-
firmed with SLNB or ALND”, “pathology was reviewed”,
“analysed and examined by pathologist” and “histopathologic
evaluation”) [10, 11, 13, 20, 21], and three studies did not
report anything about the used analysis [8, 15, 17].
Pooling of the acquired data in meta-analyses was averted
because of the very large heterogeneity of breast cancer stage
and subtypes, as well as imaging techniques and pathological
assessments used. Instead, descriptive statistics were used.
Detailed information of the selected studies is presented in
Tables 1 and 2.
Quality of included studies
Quality assessment of the included studies is summarised in
Table 3. A significant risk of bias was observed in three in-
cluded studies [9, 15, 17]. The following items scored poorly
or unclear overall: the patient selection, conduct or interpreta-
tion of the index test, conduct or the interpretation of the
reference standard, and flow and timing of the study.
Diagnostic performance of MRI in axillary lymph node
staging: Dedicated to the axilla versus covering the breast
and axilla
Of the five studies that used a dedicated axillary coil, the three
studies with T1w, T2w or dynamic contrast-enhanced (DCE)
imaging sequences had a median sensitivity of 88.4 % (range
79–94.6 %) and NPVof 94.7 % (range 87–95 %) [11, 14, 16].
Two studies using T2*w imaging sequences with USPIO, had a
lower median sensitivity (83.0 %; range 73.0–86.4 %), but a
slightly higher NPV (95.9 %; range 78.0–98.0 %) compared
to the previously mentioned three studies [18, 22]. Overall, the
median sensitivity of the five studies together was 84.7% (range
73–94.6 %) with an NPVof 95.0 % (range 78.0–98.0 %).
A coil covering both the breast and axilla was used in 11
studies [7–10, 12, 13, 15, 17, 19–21], which were divided in
two groups that used different imaging sequences. For the
studies using T1w, T2w or DCE, median sensitivity was
60.0 % (range 33.3–97.0 %) with an NPV of 80.0 % (range
1.9–99.5 %). For the studies using DWI, median sensitivity
was 84.2 % (range 53.8–97.0 %) with an NPV of 90.6 %
(range 77.8–99.4 %) [7–10, 12, 13, 15, 17, 19–21]. Overall
sensitivity and NPV were 82.0 % (range 33.3–97.0 %) and
82.6 % (range 1.9–95.7 %), respectively. More detailed study
results for articles comparing a dedicated axillary coil versus a
breast and axillary coil are summarised in Table 4.
Diagnostic performance of MRI in axillary lymph node
staging: Studies using T1w/T2w, DCE, DWI and T2*w
USPIO imaging sequences
Seven studies using dynamic, contrast-enhanced MR imaging
reported a median sensitivity of 60.0 % (range 33.3–97.0 %)
and NPVof 80.0 % (range 1.9–99.5 %) [7, 9, 11, 12, 17, 20,
21]. The remaining three imaging sequences reported a more
comparable median sensitivity and NPV of 88.4 % (range
79.0–94.6 %) and 94.7 % (range 87.0–95.0 %) for non-
enhanced T1w/T2w, 84.2 % (range 53.8–97.0 %) and
90.6 % (range 77.8–99.4 %) for DWI and 83.0 % (range
73.0–86.4 %) and 95.9 % (range 78.0–98.0 %) for T2*w
USPIO [8–10, 13–16, 18, 19, 22]. More detailed results for
different imaging sequences are summarised in Table 5.
To summarise, the most promising results seem to be
achievable when using non-enhanced T1w/T2w and USPIO-
enhanced T2*w sequences in combination with a dedicated
axillary protocol, sensitivity 84.7 % and NPV 95.0 %.
Discussion
Recent studies have shown that every single axillary metastasis
may not require surgery. For example, Giuliano et al. (2011)
showed in the ACOSOG Z011 trial that the 5-year overall
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survival of breast cancer patients with limited sentinel lymph
node metastasis, treated with breast conservation and system-
ic therapy, did not decrease when omitting an ALND
[92.5 %; 95 % confidence interval (CI), 90.0–95.1 %] com-
pared to ALND (91.8; 95 % CI, 89.1–94.5 %) [23]. Fur-
thermore, the impact of the true pathological lymph node
status on adjuvant systemic treatment recommendations ap-
pears limited, thereby eliminating the need to detect every
single (extremely small) metastasis [24]. These new insights
have created a window of opportunity for many other non-
invasive (imaging) modalities to be used in axillary lymph
node staging.
In this study we systematically reviewed the available lit-
erature on MRI’s diagnostic performance for axillary nodal
staging in breast cancer patients. We aimed to determine
whether MRI could sufficiently exclude axillary lymph node
metastasis, thereby replacing SLNB, consequently eliminat-
ing the risk of its morbidity. For this purpose, we focused on
the sensitivity and NPV, as we are mainly interested in the
exclusion of axillary metastases in order to omit SLNB.
Table 3 Presentation for QUADAS-2 results















Yoshimura et al., 1999 + ? ? + + + +
Kvistad et al., 2000 + + + + + + +
Michel et al., 2002 + + ? + + + +
Harada et al., 2006 + + ? + + + +
Orguc et al., 2012 ? ? ? ? ? ? ?
Fornasa et al., 2012 + ? ? + + + +
He et al., 2012 ? - - ? - + +
Scaranelo et al., 2012 + + + + + + +
Hwang et al., 2013 + ? ? + + + +
Luo et al., 2013 ? + ? ? + + +
Kamitani et al., 2013 + ? + ? + + +
Basara et al., 2013 ? ? - ? - + ?
Hieken et al., 2013 + ? + ? + + +
Abe et al., 2013 ? + ? ? + + +
Li et al., 2014 + + + + + + +
An et al., 2014 + + + + + + +
Low risk, High risk, Unclear risk
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Therefore, the NPV should at least be non-inferior to the NPV
of SLNB. A recent meta-analysis showed a false-negative rate
of 8.61 % (95 % CI: 8.05–9.2 %) of the SLNB [25]. The
calculated NPV of the SLNB in a patient group with a
prevalence of 40 % of axillary metastasis equals 94.5 %.
In our current observation, the most promising results seem
to be achievable when using non-enhanced T1w/T2w and
USPIO-enhanced T2*w sequences in combination with a
dedicated axillary protocol. These protocols turned out to
have a sensitivity and NPV of respectively 84.7 and
95.0 %. These results are promising, as the NPV approaches
the NPV of SLNB. However, some restraint in the clinical
implementation of axillary MRI should be considered be-
cause of the study limitations, such as: the heterogeneous
study design, overall limited study populations, inclusion of
only single-centre studies and lack of 95 % confidence in-
tervals mentioned in studies. To implement axillary MRI in
the clinical setting, these promising results should be con-
firmed in large, multicentre studies and various readers of
the examinations. In addition, a protocol that includes non-
enhanced T1w/T2w and USPIO-enhanced T2*w sequences
in combination with a dedicated axillary protocol need to be
considered as they seem to give the most promising results.
In our observations, a dedicated axillary protocol (for exam-
ple using a surface radiofrequency coil placed on the axilla) was
superior to a more standard protocol covering both the breast
and axilla in the same field of view. This is only logical, as the
use of surface coils and the reduced distance from the axillary to
the coil improves signal-to-noise ratios, enabling the use of
higher spatial resolutions. More interestingly, DWI has, despite
the use of a protocol covering the breast and axilla together, an
almost equal sensitivity (84.2 %), but a lower NPV (90.6 %)
when compared with studies using a dedicated protocol (84.7
and 95.0 %). Unfortunately, there are no studies that investigat-
ed the use of DWI sequences in a dedicated axillary protocol.
However, the clinical implementation of DWI and USPIO-
enhanced T2*-weighted imaging might be challenging. Disad-
vantages of the DWI are high sensitivity to motion artefacts,
limited spatial resolution and more pronounced artefacts at
higher field strengths. The ADC values used in diffusion-
weighted imaging are dependent on scanner and b-values.
The clinical implementation of USPIO-enhanced imaging is
hampered by the necessity of administrating the contrast 24–
36 h prior to MRI imaging. Moreover, UPSIO can cause side
effects in up to 18 % of the examinations such as rash, pruritus,
abdominal and/or lumbar pain, chest pain and an orthostatic
reaction[18]. An additional disadvantage of USPIO is that it
is not universally available and using USPIO forMR lymphog-
raphy is ‘off-label’. These disadvantages need to be overcome,
especially since the NPVapproaches the NPVof the SLNB.
Given the evidence from the Z0011 trial, there may be
relatively less utility for MRI evaluation of lymph nodal status
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be managed with ALND. The main gain however is that region-
al treatment with MRI is based on the true absence or presence
of lymph node metastases compared to traditional physical ex-
amination and/or ultrasound. Axillary ultrasoundwas never test-
ed for node-to-node evaluation and is not able to predict ‘true’
nodal status accurately. In combination with the Z0011 results
(inwhich 27%of nodalmetastases remained) created reluctance
among many clinicians to implement these results.
Axillary MRI evaluation with a high NPV could induce
omission of the SLNB in case of negative findings, which
constitute about 65 % of all breast cancer patients. Axillary
MRI with high PPV could result in an SLNB in case of limited
nodal metastases. Axillary MRI evaluation with high PPV
could further induce two pathways when extended nodal dis-
ease is observed: axillary lymph node dissection or neoadju-
vant systemic therapy and re-evaluation usingMRI after com-
pletion of all chemotherapy cycles. All this would result in
policy based on the true nodal burden instead of estimating
it to the best of our ability using ultrasound and the clinician’s
opinion regarding the Z0011 trial results.
A subgroup of patients (clinical stage T1-2 and N0 under-
going breast conservative therapy and whole-breast radiation)
would not necessarily be managed with ALND: hence the
utility of preoperative axillary MRI will depend on whether
or not the surgeon has adopted omission of ALND in patients
with minimal sentinel node disease. In order to define the
importance of MRI evaluation of axillary lymph nodes as a
replacement for SLNB, differentiation between minimal and
more advanced nodal disease (high nodal disease burden be-
ing defined as >3 metastatic nodes in the majority of studies)
must be clear. None of the selected papers compared pN status
with the number of positive lymph nodes at MRI. Only He
et al. mentioned a different diagnostic accuracy for nodes from
level I and level III. Future studies should strongly consider
the use of node-by-node analyses of the axillary lymph nodes
to test whether axillary MRI can replace SLNB.
Previously, other non-invasive techniques that were consid-
ered to exclude axillary metastases were axillary physical exam-
ination (PE), axillary ultrasound (AUS) and positron emission
tomography–computed tomography (PET/CT). However, these
methods lack sensitivity and NPV. Sensitivity is 25–35.5 % for
PE, 43.5–72.3 % for AUS and 56–62.7 % for PET/CT [12, 26].
The NPV is 81.7 % for PE, 81.6–83.3 % for AUS and 79.1 %
for PET/CT [11, 12, 27–29]. Concluding, the diagnostic perfor-
mance of these techniques is insufficient to exclude lymph node
metastases and omit SLNB. At this point, MRI seems to be the
most promising non-invasive nodal staging technique with a
highest median sensitivity of 84.7 % and NPVof 95.0 %.
Based on the QUADAS-2 tool, there was an overall good
quality of studies. Three studies were assessed as studies with
a lowmethodical quality and a high risk of bias. In the study of
Orguc et al. (2012), introduction of bias was unclear in all
domains: the patient selection, index test, reference test, flow
and timing [17]. A high risk of bias of the reference test was
observed in the studies of He et al. (2012) and Basara et al.
(2013). In the study of He et al. (2012), a physician whowas in
charge of labelling the lymph node samples took part in every
MRI examination and in the surgery of every enrolled patient
[9]. Basara et al. (2013) used histopathological examination as
a reference test for malignant lymph nodes and clinical exam-
ination with imaging findings as reference for benign lymph
nodes. Furthermore, Basara et al. (2013) and He et al. (2012)
both included patients with various indications for a conven-
tional breast MRI, not just patients with breast cancer. This
increased our concerns about whether or not this study popu-
lation is applicable to our research population.
Along with the more limited methodological quality of the
three studies mentioned above, we noticed a great variety in
the outcome of these studies compared to other (methodolog-
ically stronger) articles. Even when these three studies were
excluded, the final conclusions of our review did not change.
Study limitations
First, the included studies were very heterogeneous in their
study designs. They used different imaging sequences (T1w,
T2w, DCE, DWI and T2*w), different radiofrequency coils
and different contrast agents (gadolinium-based and USPIO).
This stopped us from pooling data and resulted in a more
descriptive analysis of the results.
Second, publication and selection bias is a study limitation
in every systematic review. The tendency to not publish stud-
ies with negative results might lead to an overestimation of our
results. By using the PRISMA approach in combination with
an extensive search, selection and inclusion, we think that the
influence of publication and selection bias is limited.
Conclusion and outlook
In summary, the diagnostic performance of MRI for assessing
axillary nodal staging in breast cancer patients is promising, as
the NPVapproaches the NPVof the SLNB.
However, current observations are based on (single-centre)
studies with heterogeneous study designs and limited popula-
tions. Thus, these finding should be interpreted with these
limitations in mind.
Based on the current findings, most desirable protocol would
be a dedicated axillary coil in combination with T1-weighted,
T2-weighted and T2*-weighted USPIO. Additionally, DWI
combined with a dedicated coil might create the opportunity
to achieve even higher diagnostic values compared to the use
of a protocol covering the breast and axilla. However, there are
no studies that used one of these specific protocols. Future
studies should consider the use of these protocols to seewhether
the diagnostic performance can be increased by this approach.
214 Insights Imaging (2015) 6:203–215
In order to further investigate the clinical use of axillary MRI
for staging of breast cancer patients, these studies should be
performed in a multicentre study comprising a large number
of patients, evaluated by multiple radiologists.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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